Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer’s disease model

BACKGROUND: Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that lacks any disease-modifying drug for the prevention and treatment. Edaravone (EDR), an approved free radical scavenger, has proven to have potential against AD by targeting multiple key pathologies including amyloi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Drug Des Devel Ther
Main Authors: Parikh, Ankit, Kathawala, Krishna, Li, Jintao, Chen, Chi, Shan, Zhengnan, Cao, Xia, Wang, Yan-Jiang, Garg, Sanjay, Zhou, Xin-Fu
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2018
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6042531/
https://ncbi.nlm.nih.gov/pubmed/30022810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S161944
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki